Navigation Links
Microbix Sales Grow 22% For Nine Months

    Burn rate significantly reduced and Semen Sexing Technology achieves

TORONTO, Aug. 6 /PRNewswire-FirstCall/ - For nine months ended June 30, 2009, Microbix Biosystems Inc. (TSX:MBX) announced strong sales and a significantly reduced burn rate. The third quarter had a small sales retraction that was related to timing of orders and changing exchange rates. The forecast is for continued growth in sales.

"The 22% sales growth achieved in the nine months ending June 30, 2009 is a trend we expect to continue in fiscal 2010. Our new manufacturing facility is fully operational, cash flow is improving and the opportunity to create shareholder value is still available in all three pipeline products albeit delayed," said William J. Gastle, CEO of Microbix.

    Third Quarter Highlights

    Core Business

In the third quarter, sales declined 7% compared to the very strong third quarter in 2008. "Fourth quarter sales are expected to be steady but the overall outlook is that demand for virology products is forecasted to continue to increase in fiscal 2010," Mr. Gastle added.

"A new product line is being launched late in 2009 that will generate revenue in the following six months. We see the growth trend in product volume enjoyed in 2009 continuing into 2010 although currency fluctuation may challenge near term sales objectives. The expanded capabilities of the Watline facility are allowing us to enter related biological markets that have the potential to grow our opportunity base significantly over our traditional markets."

Influenza Vaccine Business

"Influenza vaccine has been in the news since the emergence of the H1N1 virus in April, a virus that met the WHO criteria of a pandemic strain," said Mr. Gastle. "There is a global capacity shortage of vaccine supply as H1N1 vaccine production has only produced 25 to 50% of the yields obtained for seasonal virus strains. Several large global influenza vaccine manufacturers have reported low H1N1 yields, and Microbix' VIRUSMAX could assist these companies to improve their yields," he added.

"This represents an opportunity to widen access of VIRUSMAX to the increasing number of new influenza vaccine manufacturers globally. The Company continues to demonstrate the efficacy of the technology through collaborations with partners," Mr. Gastle said. "The Company is engaged in three activities including performance testing with H1N1 yield enhancement, completing financing for the influenza vaccine manufacturing facility in Hunan China, and the scale up of the VIRUSMAX technology under commercial conditions. Microbix expects to see more companies begin to work with the technology over the next few months."

The Company recently met with officials from Changsha National Biomedical Industrial Park in China to discuss financing and construction plans for the influenza vaccine manufacturing facility. The Hunan group have proposed to self-finance Phase I and begin construction by the second quarter of 2010. The advantage of this plan is to remove the need for the first round of financing, allowing the program to be initiated at a critical time.

Semen Sexing Technology (SST)

In this third quarter, Microbix focused on strengthening its SST intellectual property position. "This was an important milestone following a significant discovery," he continued. "Microbix' recent discoveries should provide a more cost-effective platform for semen sexing and significantly improve yields and quality of the sperm produced compared to the current commercial sexing technology. With this new technological advantage, the Company is entering discussions with interested third parties for co-development and licensing. The presence of a multi-billion dollar unregulated market for companies in the animal health field or livestock industries is attractive to many commercial players. The Microbix technology has the potential to provide a new entry company with full IP exclusivity. As previously reported term sheet agreements have already been signed with artificial insemination companies worldwide."


The Company acquired all Urokinase assets from ImaRx Therapeutics, Inc. of Tucson, Arizona, (Nasdaq: IMRX) in September 2008. These assets included ImaRx' remaining Urokinase inventory as well as the regulatory file for the product (formerly known as Abbokinase(R), now rebranded as Kinlytic(R)), key raw materials for Urokinase manufacturing, and the corresponding sales and marketing infrastructure.

"The results of our Urokinase investment have been disappointing," Mr. Gastle said. "The US FDA has not yet released the inventory of Kinlytic we acquired in September 2008. We purchased the Urokinase inventory on the premise that it was stable and releasable under an FDA approvable letter. While the FDA has conceded the data we presented has merit, at a recent meeting of appeal the FDA requested yet more stability data before they will reconsider our request. No clinical trials have been requested in order to obtain inventory release for labeled indications. The Company is currently evaluating all options for the inventory."

Microbix is one of many drug companies that are experiencing delays at the FDA today and continues to press matters with the agency," Mr. Gastle said. "We remain optimistic that we will reach the market."

Other Highlights

The Company has reduced its overhead as we transitioned virology manufacturing into the new facility. A major corporate objective is to be profitable and cash flow positive in 2010. With the additional capacity we expect to expand sales in 2010 and to see continued financial improvement for the Company."

Financial Results

For the quarter ended June 30, 2009, the Company recorded a net loss of $672,366 or one cent a share compared to a loss of $945,111 or three cents a share in the same period in fiscal 2008. The company's negative cash position improved by 99.9% to $ 26,661 for the third quarter 2009 compared to negative cash flow $ 1,079,492 in the same period in 2008.

A lower loss for the third quarter compared to 2008 reflected restructuring activities, the reduction in product pipeline expenditures and stable revenues compared to the same period in 2008. Losses associated with research and development will decline as development activities will be contributed by licensing partners.

Capital expenditures will decline as major investments are completed. Pipeline projects are going to be financed through non dilutive agreements with partners. Microbix continues its corporate restructuring to conserve cash and eliminate its burn rate in order to ensure its pipeline products reach their full potential. The growth in sales in the next 12 months is expected to be accretive to the Company's projected positive cash flows.

                                Three Months Ended       Nine months ended
                                      June 30                 June 30
                              ----------------------- -----------------------
                                    2009        2008        2009        2008
                                    ----        ----        ----        ----
                                       $           $           $           $
    Sales                      1,391,435   1,517,150   4,568,163   3,733,773

    Net Profit (loss)           -672,366    -945,111  -1,768,868  -3,227,795

    Net Profit (loss) per share    -0.01       -0.02       -0.03       -0.06

    Cash Flow                    -26,661  -1,079,492  -2,633,439   2,751,746

Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to get authorization to release Kinlytic for distribution in the US from the FDA, inability to complete financing for the Hunan China project currently the subject of financing; risks associated with commercializing the pipeline technologies; risks associated with failure to develop and commercialize SST; non-adoption of SST; risks associated with currency exchange rates which may exaggerate or reduce the actual financial performance of the Company. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
2. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
3. Microbix Announces A New Technology Platform For The SST Project
4. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
5. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
6. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
7. iCardiac Expands Sales and Marketing Team
8. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
9. New Director of Lab Sales for Polymathic Analytical Labs
10. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
11. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
Post Your Comments:
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology:
(Date:11/20/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet, ... interviewed on The RedChip Money Report television ... Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, and ... ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
Breaking Biology News(10 mins):